Drug Screening Assays, Antitumor

"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Descriptor ID	D004354
MeSH Number(s)	E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
Concept/Terms	Drug Screening Assays, Antitumor Drug Screening Assays, Antitumor Antitumor Drug Screening Assays Cancer Drug Tests Cancer Drug Test Drug Test, Cancer Drug Tests, Cancer Test, Cancer Drug Tests, Cancer Drug Drug Screening Tests, Tumor-Specific Drug Screening Tests, Tumor Specific Antitumor Drug Screens Antitumor Drug Screen Drug Screen, Antitumor Drug Screens, Antitumor Screen, Antitumor Drug Screens, Antitumor Drug Anti-Cancer Drug Screens Anti Cancer Drug Screens Anti-Cancer Drug Screen Drug Screen, Anti-Cancer Drug Screens, Anti-Cancer Screen, Anti-Cancer Drug Screens, Anti-Cancer Drug Anticancer Drug Sensitivity Tests Tumor-Specific Drug Screening Tests Tumor Specific Drug Screening Tests Dye Exclusion Assays, Antitumor Dye Exclusion Assays, Antitumor

Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Cytological Techniques [E01.370.225.500]
Drug Screening Assays, Antitumor [E01.370.225.500.388]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Cytological Techniques [E05.200.500]
Drug Screening Assays, Antitumor [E05.200.500.388]
Cytological Techniques [E05.242]
Drug Screening Assays, Antitumor [E05.242.417]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]

Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".

Drug Screening Assays, Antitumor
Tumor Stem Cell Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.

Bar chart showing 114 publications over 26 distinct years, with a maximum of 10 publications in 2010 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2000	0	2	2
2002	0	1	1
2003	0	2	2
2004	0	2	2
2005	0	2	2
2006	1	0	1
2007	1	4	5
2008	0	3	3
2009	1	4	5
2010	1	9	10
2011	0	6	6
2012	0	2	2
2013	0	5	5
2014	2	8	10
2015	0	7	7
2016	1	5	6
2017	0	8	8
2018	1	3	4
2019	1	5	6
2020	0	6	6
2021	0	7	7
2022	0	5	5
2023	0	1	1
2024	1	1	2
2025	0	5	5

Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.

Tiwari R, Delossantos J, Ghali ENHK, Chavez LA, Chaudhari VS, Han S, Chauhan SC, Yallapu MM. Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy. ACS Appl Bio Mater. 2026 May 18; 9(10):4579-4593.

View in: PubMed
Liu W, Mousa AAK, Dayer G, Hopkins AM, Campbell M, Mao Y, Jiang ZH, Lees SJ, Ramachandran R, Hou J. Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer. Bioorg Chem. 2026 07 05; 175:109807.

View in: PubMed
Rasafar N, Sanchez-Michael LA, Torres A, Andujo LA, Gutierrez DA, Varela-Ramirez A, Aguilera RJ, Noveron JC. Novel anticancer alkyl pyridinium derivative exhibits antiproliferative activity via G0/G1 cell cycle arrest and apoptosis activation in triple-negative breast cancer cells. Bioorg Med Chem. 2026 Jun; 137:118638.

View in: PubMed
Satti VR, Raza MS, Roshani K, Veeranki KC, Mondal T. Design and Synthesis of Novel Indazole-Sulfonamide Derivatives, Cytotoxicity, and Molecular Docking Insights. Chem Biodivers. 2026 Feb; 23(2):e03697.

View in: PubMed
Dickinson CF, Flipse SM, Wood JS, Bistran E, Bland AM, Sprague DJ, DeJohn AM, Choo YM, Hanna GS, Yoshida WY, Williamson RT, Tius MA, Hamann MT. Aleutianamine B, A Novel Chiral Sulfoxide Isolated from Latrunculia spp. and Generated via Semi-Synthesis, Exhibits Selectivity for Ovarian Cancer Cells. J Nat Prod. 2026 Jan 23; 89(1):73-81.

View in: PubMed
El-Bayaa MN, Srour AM, Alanzy AL, Messaoudi S, Abd-Rabou AA, Saleh A, Saleh MGA, El-Sayed WA. Synthesis, anticancer activity and computational studies of new benzimidazole-triazole-pyridine glycoside conjugates. Future Med Chem. 2025 Dec; 17(24):2927-2943.

View in: PubMed
Kassem AF, Mounier MM, Abdelglil MI, Abdelwahed S, El-Rashedy AA, Saleh A, Saleh MGA, Srour AM. Dual Anticancer and COX-2 Inhibitory Activity of Tailored Paracetamol-Alkanesulfonate Conjugates: A Promising Therapeutic Approach. Arch Pharm (Weinheim). 2025 Oct; 358(10):e70125.

View in: PubMed
Azzman N, Gill MSA, Abdullah N, Gutierrez DA, Varela-Ramirez A, Sanchez-Michael LA, Lopez-Saenz JA, Taib MNAM, Shah SAA, Aguilera RJ, Ahemad N. Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells. Bioorg Chem. 2025 10; 165:109033.

View in: PubMed
Badal S, Hwang BJ, Nelson A, Frank K, Maitre T, Nwokocha M, Thompson R, Morison B, Haraksingh R, Odero-Marah V, Ragin C. Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients. Cancer Res Commun. 2025 10 01; 5(10):1758-1770.

View in: PubMed
Mondal T, Sahoo P, Nandi SK, Kundu S, Li M, Haldar N, Kabir R, Mitra K, Roy S, Das M, Ghosh CK. Opto-magnetic optimization enhances the multimodal therapeutic and diagnostic (UCL/T1-T2W MRI) potential of GdOF against MDA-MB-231. J Mater Chem B. 2025 Aug 13; 13(32):9993-10008.

View in: PubMed

People

Explore

Similar Concepts

Top Journals